ERBB2 and breast cancer: The identification of human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive factor and target for therapy both defined HER2-positive breast cancer (HER2+ BC) and revolutionized treatment for this aggressive type of BC, improving patient survival in early BC (EBC) and advanced BC (ABC) [1,2].